Nektar Therapeutics
NKTR
145 hedge funds and large institutions have $1.43B invested in Nektar Therapeutics in 2014 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 59 increasing their positions, 45 reducing their positions, and 16 closing their positions.
311% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $2.61M
31% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 45
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
1% more funds holding
Funds holding: 144 → 145 (+1)
3% less capital invested
Capital invested by funds: $1.48B → $1.43B (-$48.3M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$29.8M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$13.4M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$11.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.69M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$5.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$22.1M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$8.82M |
| 3 |
State Street
Boston,
Massachusetts
|
-$6.61M |
| 4 |
Barclays
London,
United Kingdom
|
-$5.25M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$3.04M |
NKTR Hedge Fund Activity: Q3 2014 in Review
145 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2014, worth a combined $1.43B — down 3.3% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new NKTR positions and 16 closed out — a net gain of 2 holders — while 59 added to existing stakes and 45 trimmed.
The largest buyer was Primecap Management, adding an estimated $29.8M. The largest seller was Franklin Resources, cutting an estimated $22.1M.
- 145 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2014, up from 144 in Q2 2014.
- Funds reported $1.43B of Nektar Therapeutics stock for Q3 2014, down 3.3% quarter-over-quarter.
- 18 funds opened new Nektar Therapeutics positions in Q3 2014 and 16 closed out, a net change of +2 holders.
- The largest Nektar Therapeutics buyer in Q3 2014 was Primecap Management, an estimated $29.8M added.
- The largest Nektar Therapeutics seller in Q3 2014 was Franklin Resources, an estimated $22.1M sold.
Based on aggregated 13F filings for Q3 2014.